// App-Quantinova.ai

ABS120 : HEMOPHILIA A PATIENTS WITH PREVIOUS JOINT BLEEDS AND CONSECUTIVE ARTHROPATHY MAY BENEFIT FROM HIGHER FVIII TROUGH LEVELS: POST HOC ANALYSIS OF THE PHASE 3 PROPEL TRIAL

Researchers

Presenter

  • J. Windyga

Principal Investigators

  • R. Klamroth

  • P. Collins

  • M. Escobar

  • O. Stasyshyn

  • S. D. Tangada

  • W. Engl

  • I. Honauer

  • H.-Y. Lee

  • C. Escuriola-Ettingshausen

Medical Centers

  • Department of Disorders of Haemostasis andInternal Medicine, Institute of Haematology andTransfusion Medicine, Warsaw, Poland

  • Vivantes Klinikum Am Friedrichshain, Berlin, Germany

  • Cardiff University School of Medicine, Cardiff, United Kingdom

  • University of Texas Health Science Center at Houston - Medical School, Houston, Texas, United States

  • Academy of Medical Sciences of Ukraine, Lviv, Ukraine

  • Baxalta US Inc., a Takeda Company, Cambridge, United States

  • Baxalta Innovations GmbH, a Takeda Company, Vienna, Austria

  • Baxalta GmbH, a Takeda Company, Zürich, Switzerland

  • Haemophilie Zentrum Rhein Main, Morfelden-Walldorf, Germany

Locations

  • Poland

  • Germany

  • United Kingdom

  • United States

  • Ukraine

  • Austria

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • Propel

  • FVIII

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02585960

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved